

Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial

Received: 7 August 2024

Accepted: 4 December 2024

Published online: 3 February 2025

 Check for updates

Heike A. Bischoff-Ferrari^{1,2,3}✉, Stephanie Gängler^{1,2,3}, Maud Wieczorek^{1,2,3}, Daniel W. Belsky⁴, Joanne Ryan⁵, Reto W. Kressig⁶, Hannes B. Stähelin⁷, Robert Theiler^{1,2}, Bess Dawson-Hughes⁸, René Rizzoli⁹, Bruno Vellas^{10,11,12}, Laure Rouch^{12,13,14}, Sophie Guyonnet^{10,11,12}, Andreas Egli^{1,2}, E. John Orav^{15,16,17}, Walter Willett¹⁸ & Steve Horvath¹⁹

While observational studies and small pilot trials suggest that vitamin D, omega-3 and exercise may slow biological aging, larger clinical trials testing these treatments individually or in combination are lacking. Here, we report the results of a post hoc analysis among 777 participants of the DO-HEALTH trial on the effect of vitamin D (2,000 IU per day) and/or omega-3 (1 g per day) and/or a home exercise program on four next-generation DNA methylation (DNAm) measures of biological aging (PhenoAge, GrimAge, GrimAge2 and DunedinPACE) over 3 years. Omega-3 alone slowed the DNAm clocks PhenoAge, GrimAge2 and DunedinPACE, and all three treatments had additive benefits on PhenoAge. Overall, from baseline to year 3, standardized effects ranged from 0.16 to 0.32 units (2.9–3.8 months). In summary, our trial indicates a small protective effect of omega-3 treatment on slowing biological aging over 3 years across several clocks, with an additive protective effect of omega-3, vitamin D and exercise based on PhenoAge.

Epigenetic clocks are DNA methylation (DNAm) algorithms that combine information from measurements across the genome to quantify variations in biological versus chronological aging¹. Continuous advancements have led to the development of first-^{2,3}, second-^{4,5} and third-generation⁶ clocks. Many DNAm clocks have been associated with age-related morbidity and mortality⁷. However, evidence of an association with morbidity and mortality as well as lifestyle is the strongest for the second-generation clocks^{4,5,8} and the third-generation clock DunedinPACE⁹. Prior observational and small clinical studies have linked each of the treatments tested in the DO-HEALTH trial (vitamin D^{10,11}, omega-3 (refs. 5,12–15) and exercise^{16–21}) to modulation of epigenetic clock measures of aging and omega-3 to DNAm changes. The goal of

our analysis was to test the hypothesis that vitamin D supplementation, omega-3 supplementation and a simple home exercise program (SHEP), individually and in combination, would slow biological aging in a larger clinical trial. In the DO-HEALTH trial including all 2,157 participants, we reported that omega-3 alone reduced the rate of infections by 13% (ref. 22) and the rate of falls by 10% (ref. 23), and all three interventions combined had a significant additive benefit on reducing prefrailty by 39% (ref. 24) and incident invasive cancer by 61% (ref. 25) over a 3-year follow-up.

The DO-HEALTH Bio-Age trial included 777 of the 2,157 DO-HEALTH participants with DNAm measures at baseline and 3 years. DO-HEALTH was a multicenter randomized controlled trial designed to support

Table 1 | Baseline characteristics of the study population overall and by treatment group

Characteristic	All (<i>n</i> =777)	Vitamin D (<i>n</i> =397)	No vitamin D (<i>n</i> =380)	Omega-3 (<i>n</i> =385)	No omega-3 (<i>n</i> =392)	SHEP (<i>n</i> =388)	No SHEP (<i>n</i> =389)
Chronological age (years), mean (s.d.)	75.47 (4.47)	75.55 (4.54)	75.39 (4.40)	75.14 (4.20)	75.80 (4.70)	75.44 (4.48)	75.50 (4.46)
Female sex, <i>n</i> (%)	464 (59.7)	231 (58.2)	233 (61.3)	231 (60.0)	233 (59.4)	233 (60.1)	231 (59.4)
BMI (kg m ⁻²), mean (s.d.)	25.72 (4.04)	25.81 (4.13)	25.63 (3.96)	25.74 (3.94)	25.70 (4.15)	25.65 (3.96)	25.80 (4.13)
Years of education, mean (s.d.)	13.48 (3.50)	13.59 (3.64)	13.37 (3.34)	13.50 (3.31)	13.47 (3.67)	13.51 (3.45)	13.46 (3.54)
Healthy ager (NHS criteria), <i>n</i> (%)	403 (52.3)	212 (53.9)	191 (50.5)	211 (55.2)	192 (49.4)	200 (51.9)	203 (52.6)
Sangha comorbidity score ⁶⁰ (0–30 points), mean (s.d.)	2.66 (2.58)	2.66 (2.54)	2.66 (2.63)	2.57 (2.63)	2.74 (2.53)	2.64 (2.65)	2.68 (2.51)
25(OH)D <20 ng ml ⁻¹ , <i>n</i> (%)	263 (33.8)	132 (33.2)	131 (34.5)	123 (31.9)	140 (35.7)	119 (30.7)	144 (37.0)
25(OH)D (ng ml ⁻¹), mean (s.d.)	23.62 (8.44)	23.76 (8.56)	23.47 (8.31)	23.80 (8.54)	23.44 (8.33)	24.17 (8.53)	23.07 (8.32)
Blood omega-3s (DHA+EPA) <100 ng ml ⁻¹ , <i>n</i> (%)	296 (38.1)	152 (38.3)	144 (37.9)	144 (37.4)	152 (38.8)	140 (36.1)	156 (40.1)
Blood omega-3s (DHA+EPA) (ng ml ⁻¹), mean (s.d.)	94.32 (40.12)	93.40 (40.10)	95.29 (40.17)	94.63 (39.99)	94.02 (40.30)	92.25 (38.23)	96.39 (41.87)
Physical activity, <i>n</i> (%)							
Inactive	93 (12.0)	50 (12.6)	43 (11.3)	45 (11.7)	48 (12.2)	38 (9.8)	55 (14.1)
1–3 times per week	227 (29.2)	122 (30.7)	105 (27.6)	99 (25.7)	128 (32.7)	114 (29.4)	113 (29.0)
>3 times per week	457 (58.8)	225 (56.7)	232 (61.1)	241 (62.6)	216 (55.1)	236 (60.8)	221 (56.8)

NHS, Nurses' Health Study.

healthy longevity. It enrolled 2,157 generally healthy and active adults aged 70 years and older across five countries in Europe^{22,26}. DO-HEALTH was designed as a 2 × 2 × 2 factorial study testing the effects of vitamin D (2,000 IU per day), omega-3 (1 g per day) and SHEP (three times 30 min per week) individually and in combination over an intervention period of 3 years. Participants were randomized to one of eight treatment arms, and all were followed up with yearly examinations and in-person telephone calls every 3 months. Blood was collected at baseline and 1, 2 and 3 years of follow-up, and DNA was extracted and biobanked.

The Swiss National Foundation funded DNAm assays of samples collected at baseline and after 3 years from the Swiss subset of participants. Of the 1,006 Swiss participants in the trial, 777 provided consent for these analyses and had samples available after the application of the exclusion criteria. This group of individuals formed our analysis sample, which had the following characteristics: 59% were women; the mean age at baseline was 75 years; 30% had 25-hydroxyvitamin D (25(OH)D) levels of <20 ng ml⁻¹; 53% were healthy agers as defined in the Nurses' Health Study²⁷ (free of major chronic diseases, disabilities, cognitive impairments and mental health limitations); and 88% were physically active (29% were active one to three times per week, and 59% were active more than three times per week). The participant characteristics and allocation across treatment arms in DO-HEALTH are presented in Table 1 and Fig. 1. The Swiss participant subgroup represents a healthier and more active subgroup within the total DO-HEALTH population²⁸ (Extended Data Table 1). When Swiss participants with DNAm data were compared to Swiss participants without DNAm data, those without DNAm data were slightly older and slightly less educated but otherwise similar in all covariates assessed (Extended Data Table 1).

We focused the primary hypothesis testing on three 'second-generation' epigenetic clocks developed from analyses of mortality risk (PhenoAge⁴, GrimAge (ref. 5) and GrimAge2 (ref. 8)) and a later-generation epigenetic clock, also described as a 'third-generation' clock, developed from an analysis of longitudinal change in organ system integrity (DunedinPACE⁶). To enable comparison across studies, we also report results for 'first-generation' epigenetic clocks developed from analyses of age differences in DNAm (Horvath², Hannum³).

As a secondary analysis, we report results from an analysis of the seven DNAm-based surrogate markers of plasma proteins underlying GrimAge, which are quantitative measures in which high values correspond to a higher hazard of mortality^{5,8}. We also explore these proteins as they are known to be more responsive to metabolic dysregulation⁸. The epigenetic clocks and DNAm-based protein biomarkers are detailed in Extended Data Fig. 1 (ref. 5).

All DNAm-based biomarkers but GrimAge2 and DunedinPACE are based on the principal component (PC) approach. PC versions were computed according to the method described by Higgins-Chen et al.²⁹. For the Horvath, Hannum, PhenoAge and GrimAge clocks and the seven DNAm-based surrogate markers of plasma proteins underlying GrimAge, we analyzed versions constructed from DNAm PCs, which can offer superior technical reliability compared to the original versions of these measures²⁹. For GrimAge2 and DunedinPACE, we used the original versions as they already demonstrate high technical reliability^{5,6,8}.

Mean values of the DNAm measures of biological aging overall and by treatment at baseline and 3 years of follow-up are reported in Extended Data Table 2. Epigenetic clock associations with chronological age at baseline are shown in Extended Data Fig. 2. All clocks correlated with chronological age (PhenoAge *r* = 0.60, GrimAge *r* = 0.92, GrimAge2 *r* = 0.71, DunedinPACE *r* = 0.19). All clocks except for DunedinPACE provide estimates of biological age. For analysis, the biological age values were regressed on chronological age, and the residual values, sometimes referred to as 'age acceleration', were standardized and compared between baseline and year 3. DunedinPACE is a measure of the pace of aging; therefore, no residualization is needed as DunedinPACE was developed in a cohort in which all participants were of the same chronological age. The other clocks measure biological age and take on values similar to chronological age. For these clocks, residualization is needed to quantify how much older or younger a person is biologically relative to their chronological age. In contrast, DunedinPACE measures the rate of biological change with aging and takes on values centered around 1, representing 1 year of biological change per calendar year. Because this rate can be compared directly between people of different ages, no residualization is needed.




Fig. 1 | Flowchart of the DO-HEALTH Bio-Age trial in the Swiss subset of DO-HEALTH. The flowchart shows the allocation of participants across the eight treatment arms.

The analysis compared the change from baseline to the 3-year follow-up in the treatment groups to the change in the control group, using analysis of covariance. The model outcomes were the standardized change scores of age acceleration between the 3-year follow-up values and baseline values. Models included covariates for chronological age (continuous and spline at 85 years), sex, history of falls before study enrollment (a stratifying variable of the trial), body mass index (BMI) and study site.

Daily omega-3 supplementation reduced the age-acceleration or pace-of-aging values of three of four clocks in our primary analysis (PhenoAge difference (d) = -0.16 (95% confidence interval (CI) -0.02 to -0.30); GrimAge2 d = -0.32 (-0.06 to -0.59); DunedinPACE d = -0.17 (-0.04 to -0.31)). Vitamin D supplementation and SHEP were not associated with changes in any of the clocks. However, for PhenoAge, there was evidence of additive treatment effects for combinations of omega-3 supplementation with the other two interventions individually and together (range of values of d : -0.24 to -0.32). No additive effects across interventions were observed for GrimAge, GrimAge2 or DunedinPACE. No effect of intervention was observed for the first-generation clocks. Treatment effects are shown in Fig. 2 and numerically in Extended Data Table 3.

GrimAge can be interpreted as a linear combination of DNAm-based surrogate markers of plasma proteins. Some of these are known to be more responsive to metabolic dysregulation⁸. DNAm-based plasminogen activation inhibitor 1 (PAI-1), leptin and tissue inhibitor metalloproteinase 1 (TIMP-1) were modified by omega-3 supplementation (range of values of d = -0.31 to -0.42), and PAI-1, β 2-microglobulin (B2M), TIMP-1 and growth differentiation factor 15 (GDF-15) all showed evidence of modification by combinations of interventions (range of values of d = -0.26 to -0.53). Treatment effects are shown in Fig. 3 and numerically in Extended Data Table 4.

As predefined in the study protocol, we investigated whether treatment effects exhibited different patterns based on sex, age (70–74 versus 75+ years), BMI (≤ 25 versus > 25 kg m⁻² at baseline), baseline 25(OH)D levels (< 20 versus ≥ 20 ng ml⁻¹) and baseline polyunsaturated fatty acid levels (≤ 100 versus > 100 ng ml⁻¹). The effects of omega-3 supplementation on PhenoAge were somewhat larger for individuals with a baseline 25(OH)D level of ≥ 20 ng ml⁻¹. In addition, the additive effects of combinations of treatments on PhenoAge were somewhat larger for women and individuals with lower baseline blood levels of the omega-3s docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). Stratified treatment effects are reported in Extended Data Figs. 3–5.

Discussion

Previously in DO-HEALTH (including all 2,157 participants), we reported that omega-3 alone reduced the rate of infections by 13% (ref. 22) and the rate of falls by 10% (ref. 23), and all three interventions combined showed a significant additive benefit on reducing prefrailty by 39% (ref. 24) and incident invasive cancer by 61% (ref. 25) over a 3-year follow-up. The aim of the DNAm analysis in DO-HEALTH Bio-Age was to assess the effects of the interventions at the molecular level. Three of the four DNAm measures showed the clearest signal for omega-3, highlighting a specific and notable epigenetic response. This specificity is encouraging and supports the idea that targeted nutritional strategies can have distinct epigenetic aging effects. Moreover, the observation that individuals with lower starting levels of omega-3 exhibited larger epigenetic shifts further strengthens the case for personalized approaches. This suggests that baseline nutritional status may modulate the extent of epigenetic responsiveness, emphasizing the potential of omega-3 as a targeted intervention to influence DNAm age and, by extension, biological aging. Furthermore, the PhenoAge findings indicate additive benefits of omega-3 with vitamin D and exercise, extending the evidence from incident invasive cancer and prefrailty in DO-HEALTH to the molecular level. Additional support for an additive benefit of the three interventions comes from four of the seven GrimAge-based epigenetic biomarkers examined in our study (DNAm PAI-1, B2M, TIMP-1 and GDF-15).

Similar to recent data from the CALERIE trial⁹, the treatment effects in DO-HEALTH Bio-Age varied across the DNAm measures of aging we analyzed. Across the epigenetic clocks included in our analyses, the effect was the strongest in the second-generation clocks and DunedinPACE, consistent with evidence of lifestyle effects on these clocks from prior observational studies^{5,9,30,31}. In the CALERIE trial, caloric restriction slowed the pace of aging as measured by DunedinPACE but did not affect PhenoAge, GrimAge or the first-generation clocks⁹. In DO-HEALTH, we documented consistent effects of omega-3 treatment across PC-PhenoAge, GrimAge2 and DunedinPACE, as well as in three of the seven GrimAge plasma proteins (PAI-1, leptin and TIMP-1). We also documented an additive effect of the three treatments (omega-3, vitamin D and exercise) on PC-PhenoAge and four of the seven GrimAge plasma proteins (PAI-1, B2M, TIMP-1 and GDF-15).

The CALERIE intervention induced a 2–3% reduction in the pace of aging as measured by DunedinPACE. The effect of the DO-HEALTH interventions on DunedinPACE was somewhat more modest (about a




Fig. 2 | Treatment effects of vitamin D, omega-3 and SHEP individually and in combination on changes in DNAm measures from baseline to year 3.

a–d, Treatment effects are expressed as standardized estimates of the change in DNAm measures from baseline to year 3 at the respective 95% CI. For the PhenoAge (**a**) and GrimAge (**b**) clocks, we analyzed versions constructed from DNAm PCs, which have superior technical reliability compared to the original versions of these measures²⁹. For GrimAge2 (**c**) and DunedinPACE (**d**), we used the original versions as they already demonstrate high technical reliability^{5,6,8}. All analyses were done in samples of $n = 777$ participants sampled at baseline and the 3-year follow-up, without technical replicates. In **a–d**, estimates and 95% CIs from analyses of covariance adjusted for chronological age (continuous + spline at 85 years), sex, falls before the study, BMI, study site and the respective baseline biological age measures are shown. The graphs show the main effects under the assumption of additive effects between treatments in the $2 \times 2 \times 2$

factorial trial design; that is, comparing all individuals treated with vitamin D across the eight treatment arms of the trial to those who did not receive vitamin D (same for omega-3 and SHEP compared to control SHEP). Only for GrimAge2 (**c**) is each treatment arm compared to placebo because of treatment interactions. Consistent effects of omega-3 were observed in decelerating biological aging as measured by PhenoAge (**a**), GrimAge2 (**c**) and DunedinPACE (**d**). PhenoAge additionally showed an additive benefit between treatments, as observed for the clinical outcomes incident prefrailty²⁴ and incident invasive cancer²⁵ in the same trial. Detailed findings are shown in Extended Data Table 3. For second-generation clocks, standardized units can be converted to months of age retardation using the following equation: (standardized estimate $\times$ s.d. + mean) $\times 12$. Overall, the standardized treatment effects from baseline to year 3 were small, ranging from 0.16 to 0.32 units (2.9–3.8 months).

1% reduction in the pace of aging). However, the reductions in PhenoAge and GrimAge2 by 2.9–3.8 months over 3 years were larger. Further, even small changes in biological aging, if sustained, may have relevant effects on population health^{32–34}.

We acknowledge the limitations of our study. There is no gold standard measure of biological aging³⁵. We analyzed the best-validated epigenetic clocks, which represent the current state of the art in the field. Rather than specifying a single primary outcome variable, we focused on the consistency of findings across multiple well-validated measures of biological aging, concentrating on second-generation clocks and DunedinPACE³⁶. We recognize that DNAm measurements provide only a partial view of the biological changes associated with aging and come with certain technical limitations^{37,38}. Moreover, our analysis could make use of only two time points of data: at baseline and the 3-year follow-up. Relying on the change measured across two time points will increase the measurement error relative to three or more time points³⁹. However, these limitations should bias effect estimates toward the null, making our estimates of treatment effects conservative. Further, DO-HEALTH ran for only 3 years. Therefore, the significance of the intervention effects on the clocks for long-term survival is unknown⁸. Whether the DO-HEALTH treatments resulted in a persistent slowing of biological aging, leading to the prevention or delay of frailty and chronic disease beyond the 3-year follow-up, is currently unknown. For comparative context, recent meta-analyses report a 3–6% reduction in all-cause mortality risk with vitamin D

supplementation^{40–43}. Estimates from meta-analyses on the effect of omega-3 fatty acid supplementation on mortality are less comparable to data from DO-HEALTH, as those studies typically involved individuals at high cardiovascular risk with a reduction in mortality risk of about 3–4% (refs. 44–49).

The epigenetic clocks we analyzed in DO-HEALTH were developed to measure aging at the organism level and do not specify which organ systems may have been affected by the intervention⁵⁰. However, all three DO-HEALTH interventions were chosen to have diverse protective effects across multiple organ functions. Therefore, the outcome measures we analyzed are well aligned with the intervention.

The DO-HEALTH trial sample does not reflect the general population of adults aged 70 years and older. DO-HEALTH preselected generally healthy and active adults aged 70 years and older; within the Swiss subgroup, more than 50% met the Nurses' Health Study criteria for healthy agers at baseline. Our subgroup analyses suggested a stronger benefit of omega-3 in participants who started with lower baseline omega-3 (DHA plus EPA) blood levels. Notably, the Swiss subgroup had lower baseline blood omega-3 levels than the total DO-HEALTH population, possibly reflecting the landlocked geography of Switzerland (Extended Data Table 1), which may have supported the benefit of omega-3 supplementation on biological aging in this subsample of DO-HEALTH.

Our findings advance geroscience in two ways. First, similar to the analysis of the pioneering CALERIE trial⁹, we used epigenetic clocks




Fig. 3 | Treatment effects of vitamin D, omega-3 and SHEP individually and in combination on changes in DNAm-based surrogate biomarkers of plasma proteins based on GrimAge. a–g. For the seven DNAm-based surrogate markers of plasma proteins underlying GrimAge, we analyzed versions constructed from DNAm PCs. The seven DNAm-based biomarkers estimate the abundance of GDF-15 (a), PAI-1 (b), TIMP-1 (c), B2M (d), adrenomedullin (ADM; e), leptin (f) and cystatin C (g). All analyses were done in samples of $n = 777$ participants sampled at baseline and the 3-year follow-up, without technical replicates. In a–g,

estimates and 95% CIs from analyses of covariance adjusted for chronological age (continuous + spline at 85 years), sex, falls before the study, BMI, study site and the respective baseline DNAm-based biomarkers are shown. Omega-3 stands out as an individual treatment with a decline in three of the seven DNAm-based surrogate biomarkers of plasma proteins (PAI-1, leptin and TIMP-1). However, the data also show a consistent additive benefit of combining two or all three treatments for several plasma proteins (PAI-1, B2M, TIMP-1 and GDF-15). Detailed findings are shown in Extended Data Table 4.

to analyze the effects of interventions implemented in a randomized controlled trial designed to modify biological aging. Prior analyses of DO-HEALTH including all 2,157 participants established that the interventions had additive protective effects on incident invasive cancer²⁵ and incident prefrailty²⁴. Therefore, the positive findings for the three best-validated epigenetic clocks analyzed in our study support the geroscience hypothesis that slowing biological aging can contribute to preventing chronic diseases⁵¹. Second, our study bolsters the evidence from a randomized controlled trial for omega-3 as a single intervention and the additive benefit of a combined treatment of omega-3 and vitamin D and exercise on epigenetic clocks, especially PhenoAge. Several articles detail the processes for qualifying and validating biomarkers of biological age^{52,53}. Ideally, these measures of biological age can serve as surrogates for primary clinical outcomes. This requires demonstrating that a biomarker responds to rejuvenation therapies and mediates the link between such therapies and clinical outcomes. Consequently, data from human clinical trials, including those from the current study, are especially valuable for validating biological age indicators. However, for many epigenetic biomarkers, the underlying biological mechanisms remain incompletely understood. Finally, based on a recent publication suggesting that epigenetic age is higher at noon than at midnight⁵⁴, we note that blood sampling in DO-HEALTH was standardized to take place in the morning and in a fasting state.

In sum, our analysis provides evidence supporting the geroprotective benefits of omega-3 supplementation and also suggests the benefits of additive combinations of omega-3 supplementation with vitamin D supplementation and exercise. It also motivates further analysis of the DO-HEALTH trial. DO-HEALTH collected biospecimens at additional time points between baseline and the 3-year follow-up and included participants from four other countries in Europe. Results from our study motivate further investigation of these additional biospecimens and participants. More broadly, our findings support the application of measurements of biological aging in general and later-generation epigenetic clocks in particular in the evaluation of interventions designed to slow aging and increase health span.

Methods

We conducted new DNAm assays of stored blood biospecimens collected from the DO-HEALTH randomized controlled trial (ClinicalTrials.gov identifier: [NCT01745263](https://clinicaltrials.gov/ct2/show/study?term=NCT01745263)) and merged these data with existing clinical data from the trial. Biospecimen assays were conducted blinded to the trial interventions and outcomes in the subgroup of 777 Swiss participants with samples available at baseline and year 3. The Cantonal Ethical Committee of the Canton of Zurich approved this study (BASEC-Nr 2021-02510). Written informed consent was obtained from all participants included in the study.

Study design and participants

This randomized, double-blind, placebo-controlled trial with a $2 \times 2 \times 2$ factorial design had three primary treatment comparisons: (1) 2,000 IU per day of vitamin D compared to placebo; (2) 1 g per day of omega-3s (330 mg EPA plus 660 mg DHA from marine algae) compared to placebo; and (3) a strength-training exercise program performed for 30 min three times per week compared to an attention control exercise program focused on joint flexibility performed for 30 min three times a week. The factorial design was chosen to evaluate both the main and combined effects of the interventions. The inclusion criteria were age 70 years and older, living at home, having no major health events (no cancer or myocardial infarction) in the 5 years before enrollment, having sufficient mobility to visit the study centers without help and having good cognitive function with a Mini-Mental State Examination score of at least 24 (refs. 22,26). Participants did not receive any compensation for their involvement in the trial. The study and biobank are described at <https://do-health.eu>.

Randomization and masking

After enrollment and baseline testing, participants were randomized to one of eight treatment groups (Fig. 1) using block randomization (block sizes of 16 individuals) stratified by recruitment center, prior falls, sex and age (70–84 years or ≥ 85 years). A central randomization center in Switzerland, supported by trial software, was responsible for the blinding, treatment allocation and study intervention labeling. Participants received two gel capsules per day (vitamin D or placebo and omega-3s or placebo), identical in size, appearance, taste and weight. All capsules had coatings to prevent unblinding by aftertaste^{22,26}.

Procedures

Participants were followed up for 3 years, both with yearly clinical visits (baseline and 1, 2 and 3 years) and telephone calls every 3 months. For DO-HEALTH Bio-Age, the subgroup of 777 Swiss DO-HEALTH participants was assessed at baseline and 3 years. The trial was performed at seven centers in five countries (Switzerland, France, Germany, Portugal and Austria). The study protocol and statistical analysis plan were approved by ethics and regulatory agencies in all five countries and have been previously published^{22,26}. A data and safety monitoring board oversaw the study. Adherence to study medication was high, with 86% of the participants taking at least 80% of their total study pills; 70% of the participants performed the exercise programs at least twice per week, and 62% performed the exercise programs at least three times per week. High adherence to study medications (omega-3 and vitamin D supplements) was confirmed by changes in serum polyunsaturated fatty acid and 25(OH)D levels^{22,26}.

DNAm data

Whole blood samples from study participants were collected in PAXgene DNA tubes and registered at the DO-HEALTH Biobank of the University of Zurich. Blood aliquots were sent to the Life&Brain Center, Department of Genomics, University of Bonn, on dry ice for DNA extraction with a chemagic magnetic beads-based method. DNA aliquots were processed on the Infinium Methylation EPIC version 1.0 array (Illumina). The EPIC array quantifies 5-methylcytosine levels at $>850,000$ CpG sites across all known genes, regions and key regulatory regions. Briefly, a 500 ng amount of extracted DNA samples was bisulfite converted using the EZ-96 DNAm lightning kit (Zymo Research), and 200 ng of the converted DNA was used as input for the EPIC arrays (Illumina). EPIC arrays were processed according to the manufacturer's instructions and scanned using the Illumina iScan platform. The baseline and 36-month samples from the same individual were processed in the same array batch and on the same BeadChip to minimize batch effects. Quality control and normalization analyses were performed using the minfi (version 1.42.0) Bioconductor (version 2.46.0)⁵⁵ package for the R statistical programming environment (version 3.6.3). Probes were considered missing in a sample if they had detection P values of >0.01 and were excluded from the analysis if they were missing in $>50\%$ of the samples. Normalization to eliminate systematic dye bias in two-channel probes was carried out using the minfi default method. Following quality control and normalization, DNAm data for 866,238 CpGs were available for 777 participants of the Swiss subgroup in DO-HEALTH, both at baseline and 3 years of follow-up (Fig. 1). Beta values were extracted and used for the analysis.

Epigenetic clocks and DNAm-based protein measures

Epigenetic clocks are DNAm algorithms that combine information from measurements across the genome to quantify variation in biological aging⁴. The first-generation epigenetic clocks were developed by comparing DNAm between individuals of different chronological ages to generate age prediction algorithms. We report analyses of two well-known first-generation clocks, Horvath's multitissue clock² and the blood-based clock developed by Hannum et al.³. These clocks are highly accurate in predicting chronological age but show only weak

and inconsistent associations with morbidity and mortality^{2,3,7}. The second-generation epigenetic clocks were developed by modeling differences in mortality risk and normalizing predicted risks to age values. We analyzed two second-generation clocks: PhenoAge⁴ and GrimAge2 (ref. 8). These second-generation clocks have much greater predictive capacity for morbidity and mortality than the first-generation clocks⁵⁶.

The DunedinPACE pace-of-aging clock⁶ models differences in the rate of deterioration in organ system integrity, termed ‘pace of aging’ (ref. 57). In contrast to first- and second-generation DNAm clocks, which aim to quantify the amount of biological aging at the time of measurement, pace-of-aging clocks quantify the pace of age-related deterioration of system integrity. The DunedinPACE DNAm algorithm was derived from elastic net regression of the physiological pace-of-aging composite on Illumina EPIC array DNAm data derived from blood samples collected at the follow-up assessment at age 45 years. The CpG sites included in the DNAm dataset used to develop the DunedinPACE algorithm were restricted to those showing acceptable test–retest reliability as determined in the analysis by Sugden et al.⁵⁸. The DunedinPACE DNAm algorithm is described in detail in the paper by Belsky et al.⁶.

For the Horvath, Hannum, PhenoAge and GrimAge clocks and the DNAm-based proteins underlying the GrimAge clock, we analyzed versions constructed from DNAm PCs, which have superior technical reliability compared to the original versions of these measures. This was achieved using the computational method by Higgins-Chen et al.²⁹. The original versions of GrimAge2 and DunedinPACE demonstrate strong technical reliability⁶. Optimal test–retest reliability is a critical feature of measurements used to evaluate the impact of an intervention.

To compute GrimAge2, we submitted selected CpGs to the DNAm clock calculator hosted by the Horvath laboratory (<https://dnamage.genetics.ucla.edu/home>; last accessed March 25, 2024) to derive the five DNAm clock estimates and DNAm protein estimates. After processing by the clock calculator ($n = 790$; Fig. 1), a complete sample of $n = 777$ with baseline and follow-up measurements was available for analysis.

The PC versions of the DNAm clocks (except GrimAge2) were calculated using the R code hosted on GitHub (<https://github.com/MorganLevineLab/PC-Clocks>)²⁹ with R (version 4.2.1).

DunedinPACE was calculated for the same samples as the other DNAm variables according to the method described by Belsky et al.⁶, using the R code hosted on GitHub (<https://github.com/danbelsky/DunedinPACE/>) with R (version 4.2.1).

We first calculated the residuals of the regression of chronological age and biological age and then computed the difference between baseline and year 3. This difference was standardized (mean = 0, s.d. = 1) and was the outcome of our trial ($\Delta_{\text{year 3} - \text{baseline}}$).

Analysis

The analysis included all Swiss DO-HEALTH participants with available DNAm data at the trial baseline and the 3-year follow-up. We computed standardized change scores for all DNAm measures by comparing standardized residuals at the 3-year follow-up to those at baseline. We analyzed these change scores to test the hypothesis that omega-3 and/or vitamin D and/or exercise slow biological aging by conducting an intention-to-treat analysis comparing the change scores between participants randomized to the interventions and the control groups. We used analysis of covariance models for each of the DNAm measures. If there was no interaction between treatments, we quantified treatment effects as ‘main effects’ (for example, receiving vitamin D versus not receiving vitamin D while adjusting for other treatments). Alternatively, in the case of interactions between treatments, each treatment arm was compared to the placebo arm. The models were adjusted for chronological age (continuous and spline at 85 years), sex, history of falls before study enrollment (a stratifying variable of the trial), BMI and study site. The primary predictors were the three treatments and their interaction with time. Given multiple testing across

four second-generation clocks, we focused on identifying consistent patterns in which changes from baseline to follow-up at year 3 had 95% CIs that did not include zero.

Standardization of effect sizes

Standardization (or normalization) is useful because it allows the comparison of epigenetic biomarkers measured on different scales by placing them on a common scale.

The SAS code below standardizes the change scores (differences) for the specified variables from baseline to the 3-year follow-up. By standardizing, each measure of epigenetic age acceleration (EAA) will have a mean of 0 and an s.d. of 1. We used the PROC STANDARD procedure in SAS to standardize several measures of difference in EAA (residuals of chronological versus biological age). The following SAS code was used for this standardization:

```
PROC STANDARD DATA=eaa_data MEAN=0 STD=1 OUT=df2;
VAR d_EAA d_EAApheno d_EAAhannum d_EAAgrim d_eaagrim2
d_PoA;
RUN;
```

In this code, the *d_* prefix indicates the difference between the follow-up and baseline measures. This standardization process ensures that each difference measure has a mean of 0 and an s.d. of 1, facilitating easier comparison and analysis.

Explanation:

1. DATA = eaa_data. This specifies the input dataset named eaa_data. This dataset contains the variables that will be standardized.
2. MEAN = 0 STD = 1. These options indicate that the standardized variables should have a mean of 0 and an s.d. of 1.
3. OUT = df2. This specifies the name of the output dataset, which, in this case, is df2. The standardized variables will be stored in this new dataset.
4. VAR. This statement lists the variables to be standardized. The variables in this code are listed below.

- d_EAA
- d_EAApheno
- d_EAAhannum
- d_EAAgrim
- d_eaagrim2
- d_PoA

The *d_* prefix stands for ‘difference’, indicating that these variables represent the difference (or change) from baseline to the 3-year follow-up. For example, *d_EAA* = EAA.followUp – EAA.baseline.

Baseline descriptives

We analyzed data from all Swiss DO-HEALTH participants for whom blood DNAm data were available at baseline and the 3-year follow-up ($n = 777$). The participants had a mean age of 75.5 years (s.d. = 4.5 years), and 60% were women (Table 1). Overall, 52% met the Nurses’ Health Study definition of healthy agers; the baseline average 25(OH)D level was 23.6 ng ml^{−1} (s.d. = 8.4 ng ml^{−1}); and the baseline blood omega-3 (DHA and EPA) levels were, on average, 94.3 ng ml^{−1} (s.d. = 40.1 ng ml^{−1}). The average baseline BMI was 25.7 kg m^{−2} (s.d. = 4.0 kg m^{−2}), and 88% were physically active (29% were active one to three times per week, and 59% were active more than three times per week) based on the well-validated Nurses’ Health Study physical activity questionnaire⁵⁹. Extended Data Table 1 shows the comparison of the Swiss subset to the total DO-HEALTH sample and the Swiss participants who had incomplete DNAm data and thereby were dropped from this analysis.

DNAm clocks

For the Horvath, Hannum and PhenoAge clocks, we analyzed versions constructed from DNAm PCs, which have superior technical reliability

compared to the original versions of these measures²⁹. The original versions of the GrimAge2 and DunedinPACE clocks already demonstrate high technical reliability^{5,6,8}. All clocks except for DunedinPACE were regressed on chronological age, and residual values were calculated for analysis. DNAm clocks estimate biological age with regard to an organism's biological state in comparison to a reference population age in which this state would be typical (Extended Data Table 5).

PhenoAge clock. The PhenoAge clock is another DNAm-based biomarker developed based on the analysis of nine blood chemistry markers, age and mortality data from the US National Health and Nutrition Examination Surveys ($n = 9,926$ participants aged 18 years and older; 23 years of mortality follow-up); DNAm and blood chemistry data from the InCHIANTI (Invecchiare in Chianti) study ($n = 912$ participants aged 21–100 years); and data from the US Health and Retirement Study ($n = 3,593$ participants aged 51–100 years)⁴.

GrimAge version 1 clock. The GrimAge clock was developed as a composite biomarker of seven DNAm surrogates of seven plasma proteins⁵, a DNAm-based estimator of smoking pack-years, age, and sex in the Framingham Heart Study Offspring and Gen3 cohorts ($n = 2,751$ participants aged 24–92 years)⁵. GrimAge relies on the fact that some (but not all) plasma protein levels can be estimated based on cytosine methylation levels. We included in our analyses the seven DNAm-based GrimAge proteins that relate to kidney function, mitochondrial function, blood clotting and inflammation (Extended Data Fig. 1).

GrimAge version 2 clock. The same unique 1,030 CpGs were used to construct version 2 of GrimAge based on individuals aged between 40 and 92 years who contributed 13,399 blood samples across nine study cohorts⁸. GrimAge2 outperforms GrimAge version 1 in predicting mortality across multiple racial/ethnic groups and in terms of associations with age-related conditions such as coronary heart disease⁸.

DunedinPACE. Pace-of-aging measures estimate the rate of biological aging, defined as the rate of decline in overall system integrity. Pace-of-aging values correspond to the years of biological aging experienced during a single calendar year. A value of 1 represents the typical pace of aging in a reference population; values greater than 1 indicate a faster pace of aging; values lower than 1 indicate a slower pace of aging. Based on the analysis of the pace of aging in the Dunedin Study ($n = 817$ participants examined at ages 26, 32, 38 and 45 years), the pace of aging was measured from within-person change over time in 19 blood chemistry and organ function test metrics of system integrity⁶. DNAm was measured at age 45 years.

Statistics and reproducibility

No formal sample size calculation was performed specifically for this study. The Swiss National Science Foundation funded DNAm assays of samples collected at baseline and 36 months from the Swiss subset of DO-HEALTH participants. The study flowchart is presented in Fig. 1. Of the 1,006 Swiss participants, 790 provided consent for these analyses. Samples with insufficient DNA extraction for accurate DNAm measures and samples that showed a mismatch of predicted sex based on DNAm measures and reported sex were excluded. This resulted in a sample size of $n = 777$ participants. A preliminary power calculation, based on the number of participants with both baseline and year 3 blood samples and consent, indicated that this sample size would provide 90% power for detecting the anticipated effects. No technical replicates were run for the DNAm analysis of the EPIC array.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Data from DO-HEALTH, used in the context of this project, as well as codebooks and analytic codes, will initially be reserved for the primary researchers of the Center of Aging and Mobility Research Group to fully exploit the datasets. Subsequently, the data will be made available to external researchers according to a controlled access system. However, all data supporting the findings of this study are available from the corresponding author upon request.

Code availability

Previously published code was used in this study^{6,29}, and no new code was generated.

References

- Horvath, S. & Raj, K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. *Nat. Rev. Genet.* **19**, 371–384 (2018).
- Horvath, S. DNA methylation age of human tissues and cell types. *Genome Biol.* **14**, R115 (2013).
- Hannum, G. et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. *Mol. Cell* **49**, 359–367 (2013).
- Levine, M. E. et al. An epigenetic biomarker of aging for lifespan and healthspan. *Aging (Albany NY)* **10**, 573–591 (2018).
- Lu, A. T. et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging (Albany NY)* **11**, 303–327 (2019).
- Belsky, D. W. et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. *eLife* <https://doi.org/10.7554/eLife.73420> (2022).
- Chen, B. H. et al. DNA methylation-based measures of biological age: meta-analysis predicting time to death. *Aging (Albany NY)* **8**, 1844–1865 (2016).
- Lu, A. T. et al. DNA methylation GrimAge version 2. *Aging (Albany NY)* **14**, 9484–9549 (2022).
- Waziry, R. et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. *Nat. Aging* **3**, 248–257 (2023).
- Vetter, V. M. et al. Vitamin D supplementation is associated with slower epigenetic aging. *Geroscience* **44**, 1847–1859 (2022).
- Chen, L. et al. Effects of vitamin D3 supplementation on epigenetic aging in overweight and obese African Americans with suboptimal vitamin D status: a randomized clinical trial. *J. Gerontol. A Biol. Sci. Med. Sci.* **74**, 91–98 (2019).
- Frankhouser, D. E. et al. Dietary omega-3 fatty acid intake impacts peripheral blood DNA methylation—anti-inflammatory effects and individual variability in a pilot study. *J. Nutr. Biochem.* **99**, 108839 (2022).
- Karimi, M. et al. DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegaAD study. *Am. J. Clin. Nutr.* **106**, 1157–1165 (2017).
- Tremblay, B. L. et al. Epigenetic changes in blood leukocytes following an omega-3 fatty acid supplementation. *Clin. Epigenetics* **9**, 43 (2017).
- Lee, H.-S. et al. Modulation of DNA methylation states and infant immune system by dietary supplementation with ω -3 PUFA during pregnancy in an intervention study. *Am. J. Clin. Nutr.* **98**, 480–487 (2013).
- Spartano, N. L. et al. Association of accelerometer-measured physical activity and sedentary time with epigenetic markers of aging. *Med. Sci. Sports Exerc.* **55**, 264–272 (2023).
- Kankaanpää, A. et al. Leisure-time and occupational physical activity associates differently with epigenetic aging. *Med. Sci. Sports Exerc.* **53**, 487–495 (2021).
- Kresovich, J. K. et al. Associations of body composition and physical activity level with multiple measures of epigenetic age acceleration. *Am. J. Epidemiol.* **190**, 984–993 (2021).

19. Gale, C. R. et al. The epigenetic clock and objectively measured sedentary and walking behavior in older adults: the Lothian Birth Cohort 1936. *Clin. Epigenetics* **10**, 4 (2018).
20. Sillanpää, E. et al. Leisure-time physical activity and DNA methylation age—a twin study. *Clin. Epigenetics* **11**, 12 (2019).
21. Fiorito, G. et al. Socioeconomic position, lifestyle habits and biomarkers of epigenetic aging: a multi-cohort analysis. *Aging (Albany NY)* **11**, 2045–2070 (2019).
22. Bischoff-Ferrari, H. A. et al. Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. *JAMA* **324**, 1855–1868 (2020).
23. Bischoff-Ferrari, H. A. et al. Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. *Am. J. Clin. Nutr.* **115**, 1311–1321 (2022).
24. Gagesch, M. et al. Effects of vitamin D, omega-3 fatty acids and a home exercise program on prevention of pre-frailty in older adults: the DO-HEALTH randomized clinical trial. *J. Frailty Aging* **12**, 71–77 (2023).
25. Bischoff-Ferrari, H. A. et al. Combined vitamin D, omega-3 fatty acids, and a simple home exercise program may reduce cancer risk among active adults aged 70 and older: a randomized clinical trial. *Front. Aging* **3**, 852643 (2022).
26. Bischoff-Ferrari, H. A. et al. DO-HEALTH: vitamin D3–omega-3–home exercise–healthy aging and longevity trial—design of a multinational clinical trial on healthy aging among European seniors. *Contemp. Clin. Trials* **100**, 106124 (2021).
27. Sun, Q. et al. Adiposity and weight change in mid-life in relation to healthy survival after age 70 in women: prospective cohort study. *BMJ* **339**, b3796 (2009).
28. Schietzel, S. et al. Prevalence of healthy aging among community dwelling adults age 70 and older from five European countries. *BMC Geriatr.* **22**, 174 (2022).
29. Higgins-Chen, A. T. et al. A computational solution for bolstering reliability of epigenetic clocks: implications for clinical trials and longitudinal tracking. *Nat. Aging* **2**, 644–661 (2022).
30. Quach, A. et al. Epigenetic clock analysis of diet, exercise, education, and lifestyle factors. *Aging (Albany NY)* **9**, 419–446 (2017).
31. Jain, P. et al. Analysis of epigenetic age acceleration and healthy longevity among older US women. *JAMA Netw. Open* **5**, e2223285 (2022).
32. Scott, A. J., Ellison, M. & Sinclair, D. A. The economic value of targeting aging. *Nat. Aging* **1**, 616–623 (2021).
33. Goldman, D. P. et al. Substantial health and economic returns from delayed aging may warrant a new focus for medical research. *Health Aff. (Millwood)* **32**, 1698–1705 (2013).
34. Kaeberlein, M. It is time to embrace 21st-century medicine. *Public Policy Aging Rep.* **29**, 111–115 (2019).
35. Ferrucci, L. et al. Measuring biological aging in humans: a quest. *Aging Cell* **19**, e13080 (2020).
36. Kritchevsky, S. B. & Justice, J. N. Testing the geroscience hypothesis: early days. *J. Gerontol. A Biol. Sci. Med. Sci.* **75**, 99–101 (2020).
37. Bell, C. G. et al. DNA methylation aging clocks: challenges and recommendations. *Genome Biol.* **20**, 249 (2019).
38. Belsky, D. W. et al. Eleven telomere, epigenetic clock, and biomarker-composite quantifications of biological aging: do they measure the same thing? *Am. J. Epidemiol.* **187**, 1220–1230 (2018).
39. Parsons, S. & McCormick, E. M. Limitations of two time point data for understanding individual differences in longitudinal modeling—what can difference reveal about change? *Dev. Cogn. Neurosci.* **66**, 101353 (2024).
40. Barbarawi, M. et al. Vitamin D supplementation and cardiovascular disease risks in more than 83 000 individuals in 21 randomized clinical trials: a meta-analysis. *JAMA Cardiol.* **4**, 765–776 (2019).
41. Bjelakovic, G. et al. Vitamin D supplementation for prevention of mortality in adults. *Cochrane Database Syst. Rev.* **2014**, CD007470 (2014).
42. Bolland, M. J., Grey, A., Gamble, G. D. & Reid, I. R. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. *Lancet Diabetes Endocrinol.* **2**, 307–320 (2014).
43. Ruiz-García, A. et al. Vitamin D supplementation and its impact on mortality and cardiovascular outcomes: systematic review and meta-analysis of 80 randomized clinical trials. *Nutrients* <https://doi.org/10.3390/nu15081810> (2023).
44. Luo, S. et al. Effects of omega-3, omega-6, and total dietary polyunsaturated fatty acid supplementation in patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. *Food Funct.* **15**, 1208–1222 (2024).
45. Qi, X., Zhu, H., Ya, R. & Huang, H. Omega-3 polyunsaturated fatty acids supplements and cardiovascular disease outcome: a systematic review and meta-analysis on randomized controlled trials. *Rev. Cardiovasc. Med.* **24**, 24 (2023).
46. Yu, F. et al. Effects of omega-3 fatty acid on major cardiovascular outcomes: a systematic review and meta-analysis. *Medicine (Baltimore)* **101**, e29556 (2022).
47. Markozannes, G. et al. Dose-related meta-analysis for omega-3 fatty acids supplementation on major adverse cardiovascular events. *Clin. Nutr.* **41**, 923–930 (2022).
48. Xie, L. et al. Effects of omega-3 polyunsaturated fatty acids supplementation for patients with cardiovascular disease risks: a dose–response meta-analysis. *Am. J. Transl. Res.* **13**, 8526–8539 (2021).
49. Khan, S. U. et al. Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis. *EClinicalMedicine* **38**, 100997 (2021).
50. Ahadi, S. et al. Personal aging markers and ageotypes revealed by deep longitudinal profiling. *Nat. Med.* **26**, 83–90 (2020).
51. Sierra, F. The emergence of geroscience as an interdisciplinary approach to the enhancement of health span and life span. *Cold Spring Harb. Perspect. Med.* **6**, a025163 (2016).
52. Moqri, M. et al. Validation of biomarkers of aging. *Nat. Med.* **30**, 360–372 (2024).
53. Moqri, M. et al. Biomarkers of aging for the identification and evaluation of longevity interventions. *Cell* **186**, 3758–3775 (2023).
54. Koncavičius, K. et al. Epigenetic age oscillates during the day. *Aging Cell* **23**, e14170 (2024).
55. Huber, W. et al. Orchestrating high-throughput genomic analysis with Bioconductor. *Nat. Methods* **12**, 115–121 (2015).
56. Levine, M. E. Assessment of epigenetic clocks as biomarkers of aging in basic and population research. *J. Gerontol. A Biol. Sci. Med. Sci.* **75**, 463–465 (2020).
57. Watad, A., Belsky, V., Shoenfeld, Y. & Amital, H. Osler–Weber–Rendu syndrome. *Isr. Med. Assoc. J.* **17**, 328 (2015).
58. Sugden, K. et al. Patterns of reliability: assessing the reproducibility and integrity of DNA methylation measurement. *Patterns (NY)* <https://doi.org/10.1016/j.patter.2020.100014> (2020).
59. Wolf, A. M. et al. Reproducibility and validity of a self-administered physical activity questionnaire. *Int. J. Epidemiol.* **23**, 991–999 (1994).
60. Sangha, O., Stucki, G., Liang, M. H., Fossel, A. H. & Katz, J. N. The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. *Arthritis Rheum.* **49**, 156–163 (2003).
61. McGreevy, K. M. et al. DNAmFitAge: biological age indicator incorporating physical fitness. *Aging (Albany NY)* **15**, 3904–3938 (2023).
62. Lu, A. T. et al. DNA methylation-based estimator of telomere length. *Aging (Albany NY)* **11**, 5895–5923 (2019).

Acknowledgements

H.A.B.-F. acknowledges support from the Swiss National Science Foundation for the extraction and analysis of the DNAm assays of samples collected at baseline and 36 months from the Swiss subset of participants (grant no. 204452), as well as support from the Stiftung für Naturwissenschaftliche und Technische Forschung for the salary of a researcher. The DO-HEALTH study was funded by the Seventh Research Framework Program of the European Commission (grant agreement no. 278588, H.A.B.-F), and within this framework, also by the University of Zurich (Chair for Geriatric Medicine and Aging Research), DNP (H.A.B.-F), Roche (H.A.B.-F), NESTEC (H.A.B.-F), Pfizer (H.A.B.-F) and Streuli (H.A.B.-F). The funding organizations had no role in the design, data collection, management, analysis, interpretation of the study, writing of the manuscript or decision to submit the manuscript for publication.

Author contributions

H.A.B.-F. has full access to all study data and takes responsibility for the integrity of the data and the accuracy of the data analysis. H.A.B.-F., B.V., R.R., W.W., B.D.-H., R.T., H.B.S., R.W.K. and E.J.O. contributed to the study design. H.A.B.-F., S. Gängler, B.V., R.R., W.W., B.D.-H., R.T., H.B.S., R.W.K., A.E. and E.J.O. contributed to data collection and/or verification. S. Gängler analyzed the data, under the supervision of H.A.B.-F. and S.H. H.A.B.-F., S. Gängler, D.W.B. and S.H. contributed to data interpretation. H.A.B.-F., in collaboration with S.H., wrote the first version of the paper. H.A.B.-F., S. Gängler, M.W., D.W.B., J.R., R.W.K., H.B.S., R.T., B.D.-H., R.R., B.V., L.R., S. Guyonnet, A.E., E.J.O., W.W. and S.H. revised the paper for important intellectual content. H.A.B.-F., S. Gängler, M.W., D.W.B., J.R., R.W.K., H.B.S., R.T., B.D.-H., R.R., B.V., L.R., S. Guyonnet, A.E., E.J.O., W.W. and S.H. had final responsibility for the decision to submit the manuscript for publication.

Competing interests

S.H. is a founder of the nonprofit Epigenetic Clock Development Foundation, which has licensed several patents for epigenetic clocks (including for GrimAge) from his former employer, UC Regents.

Further, S.H. works for Altos Labs, Cambridge, UK. The other authors declare no competing interests.

Additional information

Extended data is available for this paper at <https://doi.org/10.1038/s43587-024-00793-y>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s43587-024-00793-y>.

Correspondence and requests for materials should be addressed to Heike A. Bischoff-Ferrari.

Peer review information *Nature Aging* thanks Anne Newman and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.


Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.


© The Author(s) 2025

¹Department of Geriatrics and Aging Research, University of Zurich, Zurich, Switzerland. ²Research Centre on Aging and Mobility, University of Zurich, Zurich, Switzerland. ³Department of Aging Medicine Felix-Platter, University of Basel, Basel, Switzerland. ⁴Department of Epidemiology, Butler Columbia Aging Center, Mailman School of Public Health, Columbia University, New York, NY, USA. ⁵Biological Neuropsychiatry & Dementia Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. ⁶University Department of Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland. ⁷Department of Geriatrics, University of Basel, Basel, Switzerland. ⁸Bone Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA. ⁹Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland. ¹⁰IHU HealthAge, Toulouse, France. ¹¹Institut du Vieillessement, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France. ¹²CERPOP UMR1295, University of Toulouse III, Inserm, UPS, Toulouse, France. ¹³University Paul Sabatier Toulouse III, Toulouse, France. ¹⁴Department of Pharmacy, Toulouse University Hospitals, Purpan Hospital, Toulouse, France. ¹⁵Department of Health Policy and Management, Harvard University T.H. Chan School of Public Health, Boston, MA, USA. ¹⁶Harvard Medical School, Boston, MA, USA. ¹⁷Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. ¹⁸Departments of Nutrition and Epidemiology, Harvard TH Chan School of Public Health, Harvard University, Boston, MA, USA. ¹⁹Altos Labs Limited, Cambridge, UK. ✉e-mail: Heikea.bischoff-ferrari@uzh.ch




Extended Data Fig. 1 | Second generation clocks, Pace of Aging and GrimAge-based plasma proteins explained. Overview of life-style factors associated with second generation DNAm biology of aging measures^{5,6,8} and DNA methylation based surrogate markers of plasma proteins. While DNAm clocks measure

biological aging, surrogate proteins are ordinal/quantitative measures, where high values correspond to a higher hazard of mortality^{5,8}. For more details and references on the DNAm clocks see Extended Data Table 5. Icons from Noun Project (<https://thenounproject.com/>).




Extended Data Fig. 2 | Correlation of chronological age and biological age for DNAm clocks and Pace of Aging. All DNAm measures of age correlated with chronological age at baseline in DO-HEALTH including the pan tissue Horvath clock assessed with Spearman's rank correlation coefficient. (Spearman's rank

correlation coefficient $r = 0.56$), Hannum ($r = 0.6$), PhenoAge ($r = 0.6$), GrimAge ($r = 0.92$), and GrimAge2 ($r = 0.71$). The correlation between DunedinPACE and chronological age was substantially weaker ($r = 0.19$).



Extended Data Fig. 3 | Stratified treatment effects of vitamin D, omega-3 and SHEP (simple home exercise program) individually and in combination on change of DNAm measures from baseline to year 3. Panels A and B show regression coefficients, and their 95% CI derived from analysis of covariance adjusted for chronological age (continuous + spline at 85 years), sex, falls before


study, body mass index, study site, respective baseline biological age measure. All analyses were done in $n = 777$ participants sampled at baseline and at 3-year follow-up, without technical replicates. The treatment effects in Panel A are stratified by biological sex (male vs. female) and Panel B by chronological age (70-74 vs 75+ years).



Extended Data Fig. 4 | See next page for caption.

Extended Data Fig. 4 | Stratified treatment effects of vitamin D, omega-3 and SHEP (simple home exercise program) individually and in combination on change of DNAm measures from baseline to year 3. Panels A and B show regression coefficients, and their 95% CI derived from analysis of covariance adjusted for chronological age (continuous + spline at 85 years), sex, falls before

study, body mass index, study site, respective baseline biological age measure. All analyses were done in $n = 777$ participants sampled at baseline and at 3-year follow-up, without technical replicates. The treatment effects in Panel A are stratified by BMI (≤ 25 kg/m² vs > 25 kg/m²) and in Panel B by baseline serum Vitamin D concentrations (< 20 ng/mL vs ≥ 20 ng/mL).



Extended Data Fig. 5 | Stratified treatment effects of vitamin D, omega-3 and SHEP (simple home exercise program) individually and in combination on change of DNAm measures from baseline to year 3. The forest plot shows regression coefficients stratified by serum omega-3 concentration (≤ 100 ng/mL and > 100 ng/mL), and their 95% CI derived from analysis of covariance adjusted

for chronological age (continuous + spline at 85 years), sex, falls before study, body mass index, study site, respective baseline biological age measure. All analyses were done in $n = 777$ participants sampled at baseline and at 3-year follow-up, without technical replicates.

Extended Data Table 1 | Comparison of baseline characteristics of the Swiss subgroup with and without DNAm measures and other participants of DO-HEALTH

	All DO-HEALTH	Swiss DNAm subsample	Other DO-HEALTH participants	p-value	Swiss without DNAm	p-value
N	2157	777	1380		229	
Chronological Age [years], mean (SD)	74.94 (4.45)	74.98 (4.45)	74.91 (4.45)	0.739	75.85 (5.01)	0.01
Female sex, n (%)	1331 (61.7)	464 (59.7)	867 (62.8)	0.168	144 (62.9)	0.43
BMI [kg/m ²], mean (SD)	26.32 (4.29)	25.72 (4.04)	26.66 (4.39)	9.24e-07	26.14 (4.62)	0.18
Sangha score [0-30 points], mean (SD)	3.31 (3.04)	2.66 (2.58)	3.67 (3.21)	8.00e-14	2.90 (2.77)	0.22
Years of education, mean (SD)	12.64 (4.31)	13.48 (3.50)	12.16 (4.63)	5.76e-12	12.86 (3.14)	0.02
Healthy ager (NHS criteria), n(%)	887 (41.8)	403 (52.3)	484 (35.8)	1.92e-13	108 (47.6)	0.24
25(OH)D <20ng/mL (%)	872 (40.7)	263 (33.8)	609 (44.7)	1.18e-06	82 (35.8)	0.64
25(OH)D [ng/mL], mean (SD)	22.39 (8.42)	23.62 (8.44)	21.69 (8.34)	3.20e-07	23.90 (9.14)	0.67
Blood omega-3s (DHA+EPA) ng/mL, mean(SD)	108.93 (52.62)	94.32 (40.12)	117.28 (56.93)	< 2.2e-16	98.48 (44.17)	0.18
Physical activity, n(%)				2.1e-07		0.60
inactive	375 (17.4)	93 (12.0)	282 (20.5)		32 (14.0)	
1-3 times/week	652 (30.3)	227 (29.2)	425 (30.8)		70 (30.6)	
>3 times/week	1128 (52.3)	457 (58.8)	671 (48.7)		127 (55.5)	

Extended Data Table 2 | Mean values of the DNAm measures of aging for omega-3 alone, vitamin D alone, SHEP (simple home exercise program) alone, the combination of all three treatments and placebo at baseline and 36-month follow-up

	Overall BL	Overall Year 3	Omega-3 BL	Omega-3 Year 3	Vitamin D BL	Vitamin D Year 3	SHEP BL	SHEP Year 3	All treatments BL	All treatments Year 3	Placebo BL	Placebo Year 3
Number participants	777	777	98	98	101	101	92	92	97	97	95	95
Chronological Age [yrs]	75.47 (4.47)	78.48 (4.48)	75.54 (4.50)	78.54 (4.50)	76.03 (4.79)	79.02 (4.80)	75.45 (4.61)	78.46 (4.63)	74.93 (4.01)	77.94 (4.01)	75.44 (4.37)	78.45 (4.37)
DNAmAge (Horvath) [yrs]	69.33 (5.63)	71.26 (5.80)	69.14 (5.55)	71.22 (5.62)	70.00 (5.88)	72.01 (5.88)	69.59 (5.30)	71.59 (5.30)	69.17 (5.56)	70.90 (5.70)	68.48 (5.51)	70.48 (5.46)
PCHorvath1 [yrs]	61.80 (0.91)	62.17 (0.97)	61.78 (0.98)	62.16 (1.05)	61.89 (0.89)	62.25 (0.94)	61.86 (0.89)	62.22 (0.96)	61.66 (0.79)	62.02 (0.86)	61.71 (0.87)	62.06 (0.93)
DNAmAgeHannum [yrs]	60.10 (5.05)	62.17 (5.22)	59.94 (5.25)	62.31 (5.67)	60.48 (4.54)	62.95 (4.97)	60.37 (5.46)	62.43 (5.93)	58.99 (4.73)	60.91 (4.73)	59.63 (4.98)	61.96 (4.71)
PCHannum [yrs]	69.71 (0.99)	70.06 (1.05)	69.68 (1.10)	70.06 (1.19)	69.78 (0.95)	70.16 (1.02)	69.72 (0.99)	70.11 (1.05)	69.51 (0.82)	69.83 (0.88)	69.62 (0.94)	69.96 (0.97)
DNAmPhenoAge [yrs]	56.89 (6.75)	59.13 (7.21)	56.97 (7.89)	59.44 (8.19)	57.27 (7.16)	60.08 (7.73)	56.27 (6.29)	58.38 (6.98)	56.14 (6.38)	57.84 (6.72)	56.30 (5.63)	59.35 (5.95)
PCPhenoAge [yrs]	61.68 (1.24)	62.04 (1.32)	61.64 (1.38)	62.03 (1.47)	61.75 (1.19)	62.13 (1.29)	61.70 (1.33)	62.13 (1.40)	61.42 (1.16)	61.70 (1.24)	61.56 (1.16)	61.99 (1.14)
DNAmGrimAge [yrs]	71.50 (4.68)	73.66 (4.82)	71.30 (4.47)	73.26 (4.76)	72.36 (4.97)	74.55 (5.11)	71.48 (4.83)	73.77 (5.03)	71.17 (4.44)	73.23 (4.74)	71.05 (4.35)	73.44 (4.46)
PCGrimAge [yrs]	82.02 (3.29)	84.02 (3.30)	82.00 (3.31)	83.97 (3.34)	82.46 (3.43)	84.44 (3.45)	82.05 (3.46)	84.06 (3.46)	81.63 (3.12)	83.63 (3.14)	81.92 (3.11)	83.95 (3.07)
DNAmGrimAge2 [yrs]	74.46 (4.76)	76.48 (4.90)	74.39 (4.54)	76.03 (4.91)	75.20 (5.16)	77.26 (5.23)	74.32 (4.80)	76.64 (5.01)	73.99 (4.66)	75.91 (4.99)	73.87 (4.47)	76.22 (4.48)
DunedinPACE [years of biological change per calendar year]	0.97 (0.10)	0.98 (0.10)	0.98 (0.10)	0.98 (0.10)	0.96 (0.10)	0.97 (0.10)	0.98 (0.10)	0.99 (0.10)	0.96(0.09)	0.96 (0.10)	0.95n (0.10)	0.96 (0.10)

Extended Data Table 3 | Treatment effects of vitamin D, omega-3 and SHEP (simple home exercise program) individually and in combination on the change of DNAm measures from baseline to year 3

Difference (95%CI) per 1 SD								
Second Generation Clocks and Pace of Aging				First Generation Clocks		Additional clocks as per reviewer's request		
Treatment	Δ PC-PhenoAge #	Δ PC-GrimAge #	Δ GrimAge2 **	Δ DunedinPACE #	Δ PC-DNAmAge Horvath #	Δ PC-HannumAge #	Δ PC-DNAm Telomere length#	Δ DNAmFitAge #
Mean change from baseline (SD) [years]	-0.16 (0.49)	-0.1(0.22)	-0.002(1.99)	0.008(0.06)	-0.008 (0.21)	-0.06 (0.28)	-0.0002 (0.008)	0.018 (2.06)
Vitamin D	-0.08 (-0.22; 0.06)	-0.001(-0.14; 0.14)	-0.07 (-0.33; 0.2)	0.02 (-0.11; 0.16)	0.03 (-0.1; 0.17)	0.01 (-0.13; 0.15)	0.04 (-0.1; 0.18)	0.06 (-0.07; 0.2)
Omega-3	-0.16 (-0.3; -0.02)	-0.1 (-0.23; 0.04)	-0.32 (-0.59; -0.06)	-0.17 (-0.31; -0.04)	-0.07 (-0.21; 0.07)	-0.09 (-0.23; 0.05)	0.18 (0.03; 0.32)	-0.11 (-0.25; 0.03)
SHEP	-0.08 (-0.22; 0.06)	0.01 (-0.12; 0.15)	0.01 (-0.26; 0.28)	0 (-0.13; 0.14)	0.06 (-0.08; 0.2)	-0.05 (-0.19; 0.1)	0.12 (-0.02; 0.26)	-0.01 (-0.15; 0.13)
Vitamin D+omega-3	-0.24 (-0.44; -0.04)	-0.1 (-0.29; 0.1)	-0.09 (-0.36; 0.18)	-0.15 (-0.34; 0.04)	-0.04 (-0.23; 0.16)	-0.08 (-0.28; 0.12)	0.21 (0.01; 0.41)	-0.05 (-0.24; 0.15)
Vitamin D+SHEP	-0.16 (-0.36; 0.03)	0.01 (-0.18; 0.21)	-0.15 (-0.42; 0.11)	0.03 (-0.16; 0.22)	0.09 (-0.1; 0.29)	-0.03 (-0.23; 0.17)	0.16 (-0.04; 0.36)	0.05 (-0.14; 0.24)
Omega3+SHEP	-0.24 (-0.44; -0.04)	-0.08 (-0.28; 0.11)	-0.2 (-0.47; 0.07)	-0.17 (-0.36; 0.02)	-0.01 (-0.21; 0.18)	-0.14 (-0.34; 0.06)	0.30 (0.1; 0.5)	-0.12 (-0.32; 0.07)
All treatments	-0.32 (-0.56; -0.08)	-0.08 (-0.32; 0.16)	-0.17 (-0.44; 0.1)	-0.15 (-0.38; 0.09)	0.02 (-0.22; 0.26)	-0.12 (-0.37; 0.12)	0.33 (0.09; 0.58)	-0.06 (-0.3; 0.18)

Treatment effects are expressed as standardized estimates of the change in DNAm measure from baseline to year three at the respective 95%CI. All analyses show main effects under the assumption of additive effects between treatments in the 2x2x2 factorial trial design, that is comparing all individuals treated with vitamin D across the 8 treatment arms of the trial compared with those who did not receive vitamin D (same for omega-3 and SHEP compared to control SHEP). Only for GrimAge2 each treatment arm is compared to placebo, because of treatment interactions. There is consistency for omega-3 slowing biological aging as measured by PhenoAge, GrimAge2 and Pace of Aging. PhenoAge additionally shows the additive benefit between treatments. There was no significant treatment effect on the change in DNAmFitAge⁶¹ over three years. Additionally, the combination of Vitamin D and omega-3 (0.21(0.01;0.41)), the combination of SHEP and omega-3 (0.30 (0.1;0.5)), as well as the combination of all three treatments (0.33 (0.09;0.58)) significantly increases PC-DNAmTL over three years. DNAmTL is not a good proxy for telomere length (weak correlation of around 0.35). However, DNAmTL has a stronger relationship to age, smoking, obesity, mortality risk) than actual leukocyte telomere length based on Southern blotting or PRC measures⁶². The table shows regression coefficients, and their 95% CI derived from analysis of covariance adjusted for chronological age (continuous + spline at 85 years), sex, falls before study, body mass index, study site, respective baseline biological age measure. All analyses were done in n=777 participants sampled at baseline and at 3-year follow-up, without technical replicates To derive the effect of each treatment in month the respective estimate needs to be multiplied by the standard deviation and by 12. To translate effect units to months: (Standardized estimate* SD + mean)*12; that is (-0.16*0.49-0.16)*12*=2.9 months; (-0.32*0.49-0.16)*12=-3.8 months. See Fig. 2 – visual display of the same findings.

Extended Data Table 4 | Treatment effects of vitamin D, omega-3 and SHEP (simple home exercise program) individually and in combination on change of DNAm-based surrogate biomarkers of plasma proteins based on GrimAge

	Difference (95%CI) per 1 SD						
	Δ PC-DNAm GDF15#	Δ PC-DNAm PAI-1**	Δ PC-DNAm TIMP-1**	Δ PC-DNAm B2M**	Δ PC-DNAm ADM**	Δ PC-DNAm Leptin**	Δ PC-DNAm CystatinC#
Mean change from baseline (SD)	0.004 (2.34)	0.013 (135.00)	-0.14 (26.40)	15.52 (3069.75)	-0.004 (0.59)	-3.62 (33.60)	6.43 (697.38)
Vitamin D	-0.07 (-0.21; 0.07)	-0.16 (-0.44; 0.12)	-0.18 (-0.46; 0.09)	-0.05 (-0.32; 0.22)	-0.26 (-0.54; 0.01)	-0.27 (-0.55; 0.01)	-0.02 (-0.16; 0.12)
Omega-3	-0.1 (-0.24; 0.04)	-0.33 (-0.61; -0.05)	-0.31 (-0.59; -0.04)	-0.13 (-0.41; 0.14)	-0.13 (-0.41; 0.15)	-0.42 (-0.7; -0.14)	-0.06 (-0.2; 0.08)
SHEP	-0.09 (-0.23; 0.05)	-0.18 (-0.46; 0.1)	-0.06 (-0.34; 0.22)	0.2 (-0.07; 0.48)	-0.31 (-0.59; -0.03)	-0.23 (-0.52; 0.06)	0.07 (-0.08; 0.21)
Vitamin D + omega-3	-0.17 (-0.37; 0.03)	-0.43 (-0.71; -0.14)	-0.28 (-0.56; 0)	-0.08 (-0.35; 0.19)	-0.39 (-0.67; -0.12)	-0.39 (-0.67; -0.1)	-0.08 (-0.28; 0.12)
Vitamin D +SHEP	-0.16 (-0.35; 0.04)	-0.4 (-0.68; -0.13)	-0.29 (-0.56; -0.01)	0.09 (-0.18; 0.36)	-0.46 (-0.74; -0.18)	-0.34 (-0.62; -0.06)	0.04 (-0.15; 0.24)
Omega3 +SHEP	-0.19 (-0.39; 0.01)	-0.53 (-0.81; -0.25)	-0.4 (-0.68; -0.12)	-0.14 (-0.42; 0.13)	-0.25 (-0.53; 0.03)	-0.47 (-0.76; -0.19)	0.01 (-0.19; 0.21)
All treatments	-0.26 (-0.51; -0.02)	-0.35 (-0.63; -0.07)	-0.29 (-0.57; -0.01)	-0.28 (-0.56; -0.01)	-0.26 (-0.54; 0.01)	-0.24 (-0.52; 0.04)	-0.01 (-0.26; 0.23)

The seven DNA methylation based estimators of plasma proteins estimate plasminogen activation inhibitor 1 (DNAm PAI-1), beta-2 microglobulin (DNAm B2M), adrenomedullin (DNAm ADM), leptin (DNAm Leptin), tissue inhibitor metalloproteinase 1 (DNAm TIMP-1), growth differentiation factor 15 (DNAm GDF-15), cystatin C (DNAm Cystatin C). For the seven DNAm-based proteins, omega-3 stands out as an individual treatment with a decline in three of seven DNAm-based surrogate biomarkers of plasma proteins (PAI-1, Leptin, TIMP-1). However, the data also shows consistency of an additive benefit combining two or all three treatments for several plasma proteins (PAI-1, B2M, TIMP-1, GDF-15) See Fig. 3 – visual display of the same findings. The table shows regression coefficients, and their 95% CI derived from analysis of covariance adjusted for chronological age (continuous + spline at 85 years), sex, falls before study, body mass index, study site, respective baseline DNAm surrogate marker. All analyses were done in n=777 participants sampled at baseline and at 3-year follow-up, without technical replicates.

Extended Data Table 5 | DNAm clocks and pace-of-aging measures included in the DO-HEALTH analysis

DNAm clocks	
Horvath clock	Based on analysis of samples from 82 individual datasets, which assess DNA methylation levels in 51 different tissues and cell types (n=7,844 samples in total, participants aged 0–101 yr) ²
Hannum clock	Based on analysis of whole blood samples from two different cohorts (n=426 Caucasian participants and n=230 Hispanic participants, aged 19–101 yr) ³
PhenoAge clock	Based on analysis of nine blood chemistry markers, age and mortality data from the US National Health and Nutrition Examination Surveys (n = 9,926 participants aged 18 yr and older; 23 yr of mortality follow-up); DNAm and blood chemistry data from the InCHIANTI Study (n = 912 participants aged 21–100 yr); and the US Health and Retirement Study (n = 3,593 participants aged 51–100 yr) ⁴
GrimAge clock	Based on analysis of seven plasma protein markers, smoking pack years, age, sex and mortality data from the Framingham Heart Study Offspring Cohort (n = 2,356 participants aged 24–92 yr) ⁵
GrimAge2 clock	Based on analysis of nine plasma protein markers, smoking pack years, age, sex and mortality data from the Framingham Heart Study (n=2,544 participants aged 40–92 yr) ⁸
Pace of aging	
DunedinPACE	Based on analysis of pace of aging in the Dunedin Study (n = 817 participants examined at ages 26, 32, 38 and 45 yr) Pace of aging was measured from within-person change over time in 19 blood chemistry and organ function test metrics of system integrity. DNAm was measured at age 45 yr. ⁶

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | | |
|-------------------------------------|--|
| n/a | Confirmed |
| ☐ | ☒ The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement |
| ☐ | ☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| ☐ | ☒ The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| ☐ | ☒ A description of all covariates tested |
| ☐ | ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| ☐ | ☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| ☐ | ☒ For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted
<i>Give P values as exact values whenever suitable.</i> |
| ☒ | ☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| ☒ | ☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| ☐ | ☒ Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	Software for data collection was custom made and provided by Ferrari Data Solutions.
Data analysis	Data analysis was performed with R (version 4.2.1) and SAS (version 9.4). Quality control and normalization analyses were performed using the minfi (v.1.42.0) Bioconductor (v.2.46.0)55 package for the R statistical programming environment (v.3.6.3). To compute GrimAge2 and the DNAm-based protein estimates included in the GrimAge clock, selected CpGs were submitted to the DNA methylation clock calculator hosted by the Horvath Lab (https://dnamage.genetics.ucla.edu/home ; 19.03.2024) to derive the five DNAm clock estimates and DNAm protein estimates. PC versions of the PhenoAge, Horvath, and Hannum epigenetic clocks were computed for the same samples as the GrimAge DNAm proteins according to the method described by Higgins-Chen et al.29 using the R code hosted on GitHub (https://github.com/MorganLevineLab/PC-Clocks) using R (version 4.2.1). DunedinPACE was calculated for the same samples as the other DNAm variables according to the method described by Belsky et al.6 using the R code hosted on GitHub (https://github.com/danbelsky/DunedinPACE/) using R (version 4.2.1). Additional batch correction was performed by residualizing DNAm measurements for PCs estimated from array control-probe beta values for the four clocks DNAmAge, DNAmHannumAge, DNAmPhenoAge and DNAmGrimAge and its single elements using the code provided by Higgins-Chen et al. on GitHub (https://github.com/MorganLevineLab/PC-Clocks) using R (version 4.2.0).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Data used in the context of this study will initially be reserved for the primary researchers of the Center of Aging and Mobility Research Group to fully exploit the datasets. Subsequently, the data will be made available to external researchers according to a controlled access system. However, all data supporting the findings of this study are available from the corresponding author upon request.

Code used to generate the variables in this study has been published previously as referenced in the text, thus code sharing is not applicable to this study.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender

We collected the biological sex of participants, which was assigned. All study participants provided written, informed consent. However, as predefined in the study protocol, we tested whether the treatment effects varied by sex. Since the interaction for the main findings was not statistically significant, the findings of the present study apply to all sexes.

Reporting on race, ethnicity, or other socially relevant groupings

No variable related to race, ethnicity or socially relevant grouping have been used in the study.

Population characteristics

Participants had mean age of 75.5yr (s.d.=4.5), 60% were women. Overall, 52% met the Nurses' Health Study definition for healthy agers, baseline average 25(OH)D status was 23.6 ng/ml (s.d. = 8.4) and baseline blood omega-3 levels (DHA and EPA) were on average 94.3 ng/ml (s.d. = 40.1). Average baseline BMI was 25.7 kg/m² (s.d. = 4.0) and 88% were physically active (29% moderately and 59% vigorously), based on the well-validated Nurses' Health Study physical activity questionnaire. More details can be found in Table 1.

Recruitment

DO-HEALTH participants were recruited through mailing lists of retirement authorities, churches, and other community services, posters, flyers, public events, advertisement in newspapers and other media, public events and educational programs and health care. The advertisements contained a contact phone number for each specific recruitment site that potential participants were asked to call for further information (DO-HEALTH telephone hotline – established at each recruitment site).

Ethics oversight

The Cantonal Ethical Committee of the Canton of Zurich approved this study (BASEC-Nr 2021-02510)

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

No formal sample size calculation was performed specifically for this analysis. The Swiss National Science Foundation funded DNAm assays for samples collected at baseline and at 36 months from the Swiss subset of DO-HEALTH participants. Of the 1,006 Swiss participants, 777 provided consent for these analyses and had samples available after applying exclusion criteria. A preliminary power calculation, based on the number of participants with both baseline and year 3 blood samples and consent, indicated that this sample size would provide 90% power for detecting the anticipated effects.

Data exclusions

Data were excluded from the analysis due to lack of follow-up or approval for genetic analyses, low quality of DNA extraction, gender mismatch, and absence of follow-up measurements. More details can be found in Figure 1.

Replication

Due to funding limitations, resources were allocated exclusively to the main analyses, and replication studies were not conducted at this time.

Randomization

After enrollment and baseline testing, participants were randomized to 1 of 8 treatment groups (Figure 1) using block randomization (block sizes of 16 individuals) stratified by recruitment center, prior falls, sex, and age (70-84 years or ≥85 years). A central randomization center in Switzerland, supported by trial software, was responsible for the blinding, treatment allocation, and study intervention labeling.

Blinding

All examinations and assessments were performed by trained and certified study staff using standardized methods. Participants, staff dispensing study pills and collecting outcomes, and data analysts were masked to group assignment. A physiotherapist not involved in the assessments provided instructions on the exercise programs.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

Methods

- n/a
- Involvement in the study
- ☒ ☐ Antibodies
- ☒ ☐ Eukaryotic cell lines
- ☒ ☐ Palaeontology and archaeology
- ☒ ☐ Animals and other organisms
- ☐ ☒ Clinical data
- ☒ ☐ Dual use research of concern
- ☒ ☐ Plants

- n/a
- Involvement in the study
- ☒ ☐ ChIP-seq
- ☒ ☐ Flow cytometry
- ☒ ☐ MRI-based neuroimaging

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration NCT01745263

Study protocol The study protocol has been published in Bischoff-Ferrari, H. A. et al. Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial. JAMA 324, 1855-1868 (2020)

Data collection The trial was performed at 7 recruitment centers located in 5 European countries: Switzerland (University of Zurich, Basel University Hospital, Geneva University Hospital), France (University of Toulouse Hospital Center), Germany (Charité Berlin), Portugal (University of Coimbra), and Austria (Innsbruck Medical University) between December 2012 and November 2017.

Outcomes We focus the primary hypothesis testing on three “second-generation” epigenetic clocks developed from analyses of mortality risk (PhenoAge, GrimAge and GrimAge2), and a later-generation epigenetic clock, also described as a “third-generation” clock, developed from analysis of longitudinal change in organ-system integrity, DunedinPACE. In the interest of enabling comparison across studies, we also report results for “first-generation” epigenetic clocks developed from analyses of age differences in DNAm (Horvath, HannumAge). Whole blood samples of study participants were collected in PAXgene DNA tubes and registered at the DO-HEALTH Biobank at the University of Zurich. Blood aliquots were sent to Life&Brain, Dept. of Genomics, Bonn, Germany on dry ice for DNA extraction by chemagic magnetic beads-based method. DNA aliquots were processed on Illumina Infinium Methylation EPIC v1.0 array (Illumina Inc.). Following quality control and normalization, DNAm data for 866,238 CpGs were available for 777 participants of the Swiss subgroup in DO-HEALTH, both at baseline and 36 months follow-up. Beta values were extracted and used for the analysis. The outcomes of the present study were the change in DNAm measures of biological aging between baseline and 36 months of follow-up. Model outcomes were standardized change scores of age acceleration between 36-month follow-up values and baseline values. Change scores were scaled to a mean of 0 and a standard deviation of 1 so that effect sizes can be interpreted as standardized differences between means.

Plants

Seed stocks Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.

Novel plant genotypes Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.

Authentication Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosaicism, off-target gene editing) were examined.